Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case-control study.

Laura VertechySerena Maria BocciaGiordana TiberiGiacomo AvesaniGiacomo CorradoAnna Fagotti Giovanni ScambiaClaudia Marchetti

Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2023)

Pegylated liposomal doxorubicin/trabectedin might be an alternative option to platinum-based treatment in patients experiencing disease progression during PARP inhibitor maintenance with an acceptable toxicity profile. This might be a therapeutic option in this setting, sparing platinum compounds for subsequent relapse.

Keyphrases

dna damage
dna repair
drug delivery
cancer therapy
oxidative stress
recombinant human
minimally invasive
oxide nanoparticles